Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Bangor Savings Bank

Bangor Savings Bank trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,553 shares of the pharmaceutical company’s stock after selling 171 shares during the quarter. Bangor Savings Bank’s holdings in Vertex Pharmaceuticals were worth $2,236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at about $25,000. Highline Wealth Partners LLC acquired a new position in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Dunhill Financial LLC raised its holdings in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. GHP Investment Advisors Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $29,000. Finally, Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at $33,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of research reports. Bank of America lowered their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. HC Wainwright reduced their price target on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a research report on Friday, December 20th. Canaccord Genuity Group upped their price objective on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a report on Wednesday, November 6th. Finally, Truist Financial reduced their target price on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $494.04.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $402.49 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The business has a 50 day simple moving average of $453.89 and a two-hundred day simple moving average of $469.70. The stock has a market capitalization of $103.65 billion, a P/E ratio of -202.26 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the firm posted $3.67 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.